BioWorld Science - Articles

Cancer

Roche divulges EGFR mutant inhibitors for NSCLC

Dec. 4, 2023

An F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes indole derivatives acting as EGFR L858R mutant, T790M/L858R double mutant, T790M/L858R/C797S triple mutant and/or L858R/C797S double mutant allosteric inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).

Cancer

Wake Forest University designs doxorubicin codrugs with reduced cardiotoxicity

Dec. 4, 2023

Work at Wake Forest University has led to the development of an H2O2-responsive doxorubicin hybrid codrug able to release H2S (acting as cardioprotective agent). They are reported to be useful for the treatment of cancer.

Cancer

New NLRP3 inflammasome inhibitors reported in Ventus Therapeutics patent

Dec. 4, 2023

Ventus Therapeutics US Inc. has disclosed oxoindolinyl amide derivatives acting as NLRP3 inflammasome inhibitors. As such, they are reported to be useful for the treatment of cancer, metabolic, autoimmune diseases, liver, renal, respiratory, cardiovascular and inflammatory disorders, among others.

Ocular

Character Biosciences patents new polypeptides for AMD

Dec. 4, 2023

A Character Biosciences Inc. patent describes polypeptides acting as low-density lipoprotein receptor (LDLR) ligands and reported to be useful for the treatment of age-related macular degeneration (AMD).

Microscope with laptop displaying histology image.

Cancer

Discovery of dual-target inhibitors of microtubule polymerization and JAK2

Dec. 4, 2023

Synthesis and optimization of substituted 2-amino[1,2,4]-triazolopyrimidines and related heterocycles by Wuyi University investigators has led to the identification of compound [I], and its water-soluble phosphate sodium salt prodrug, compound [II].

Cancer

TPT-004, a tryptophan hydroxylase inhibitor with efficacy in MC38 mouse colon carcinoma model

Dec. 4, 2023

Trypto Therapeutics GmbH scientists have discovered novel tryptophan hydroxylase (TPH) inhibitors, which are being developed for the treatment of colorectal cancer.

Neurology/Psychiatric

Favorable preclinical profile of investigational gene therapy for TLE reported

Dec. 4, 2023

Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy characterized by recurrent seizures originating in the hippocampus and with sprouting of mossy fiber axons that contribute to new recurrent synaptic excitability in the dentate gyrus (DG).

Substance Use & Poisoning

Novel AChE reactivator to reverse acetylcholine accumulation in the brain

Dec. 4, 2023

Organophosphorus compounds (OPs) include several types of chemical compounds used as pesticides, herbicides or nerve agents in chemical warfare that, once in the body, act by inhibiting acetylcholinesterase (AChE) functions leading to an excessive increase of acetylcholine that ultimately causes death after respiratory failure.

Neurology/Psychiatric

Psychogenics licenses rights to ENT1 inhibitor for neuropsychiatric disorders

Dec. 4, 2023

PGI Drug Discovery LLC, the drug discovery arm of Psychogenics Inc., has entered into an exclusive license agreement with F. Hoffmann-La Roche Ltd. to obtain global development, manufacturing and commercialization rights to RO-7117997. Psychogenics intends to evaluate RO-7117997 as a potential treatment for several psychiatric and neurological conditions.

Neurology/Psychiatric

Iama Therapeutics’ IAMA-6 shows promise in preclinical mesial temporal lobe epilepsy

Dec. 4, 2023

Intracellular chloride levels are crucial for physiological brain development and correct functioning. On the other hand, aberrant expression of chloride importer NKCC1 (basolateral Na-K-Cl symporter, SLC12A2) and exporter KCC2 (K-Cl cotransporter 2, SLC12A5) is involved in neurodevelopmental and neurologic conditions, including mesial temporal lobe epilepsy (MTLE), among others, leading to an imbalance between excitatory and inhibitory signals.